DOCSLIB.ORG

Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, [email protected]

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, Mmohamed@Health.Usf.Edu University of South Florida Scholar Commons Graduate Theses and Dissertations Graduate School July 2017 Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, [email protected] Follow this and additional works at: http://scholarcommons.usf.edu/etd Part of the Pathology Commons Scholar Commons Citation Mohamed, Mai, "Role of Amylase in Ovarian Cancer" (2017). Graduate Theses and Dissertations. http://scholarcommons.usf.edu/etd/6907 This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact [email protected]. Role of Amylase in Ovarian Cancer by Mai Mohamed A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Pathology and Cell Biology Morsani College of Medicine University of South Florida Major Professor: Patricia Kruk, Ph.D. Paula C. Bickford, Ph.D. Meera Nanjundan, Ph.D. Marzenna Wiranowska, Ph.D. Lauri Wright, Ph.D. Date of Approval: June 29, 2017 Keywords: ovarian cancer, amylase, computational analyses, glycocalyx, cellular invasion Copyright © 2017, Mai Mohamed Dedication This dissertation is dedicated to my parents, Ahmed and Fatma, who have always stressed the importance of education, and, throughout my education, have been my strongest source of encouragement and support. They always believed in me and I am eternally grateful to them. I would also like to thank my brothers, Mohamed and Hussien, and my sister, Mariam. I would also like to thank my husband, Ahmed. You have all been a bottomless source of strength, encouragement, and love throughout my Ph.D. Thank you. I love you. I would like to thank Dr. Kruk. Your continued support and patience are the reasons I was able to get his far. I would like to thank Stephanie Buttermore, my lab mate, for keeping me sane on my craziest days. Acknowledgements It is a pleasure to thank all of those who made this dissertation possible. I want to sincerely thank Dr. Patricia Kruk for accepting me into her lab and for her guidance, support, and patience over the years. The lessons and skills I learned from her during my time her lab will be invaluable in my future endeavors. I would like to thank my committee members, Dr. Paula C. Bickford, Dr. Meera Nanjundan, Dr. Marzenna Wiranowska, and Dr. Lauri Wright for their time and valuable insight on my dissertation research. I would also like to thank Dr. Eric Bennett for welcoming me into the program, as well as the rest of the Medical Sciences program and Pathology and Cell Biology departmental staff who have provided support for me during my time at the University of South Florida. Finally, thank you to all of the Kruk Lab members, past and present. Special thanks to my current fellow lab member: Stephanie Buttermore for her insight and for always making my time at the lab such a fun and entertaining experience. Finally, I would like to thank my family and friends for encouraging me over the last four years. It has been a long road that I would not have been able to travel on my own. Table of Contents List of Tables v List of Figures vi List of Abbreviations viii Abstract xiii Chapter 1 Overview of Ovarian Cancer Biomarkers 1 Ovarian Cancer 1 Literature-derived OC protein biomarkers 3 Cytokines and growth factors 5 Interleukin-6 (IL-6) 5 Interleukin-8 (IL-8) 5 Interleukin-10 (IL-10) 6 Prolactin (PRL) 6 Transforming growth factor beta 1 (TGF-β1) 6 Tumor necrosis factor alpha (TNFα) 7 Vascular endothelial growth factor (VEGF) 7 Structural and extracellular matrix proteins 8 Transmembrane proteins 8 Claudin-3 and -4 8 Mucin 1 (MUC1) 9 Mucin 4 (MUC4) 9 Mucin 16 (CA125) 9 Structural and matrix-related proteins 10 Collagen (COL1A1 and COL11A1) 10 Human plasminogen activator inhibitor-1 (PAI-1) 10 Kallikrein (KLK-10,-11) 11 Matrix metalloproteinases (MMP-2 and -9) 12 Osteopontin (SPP1) 12 Stress induced phosphoprotein 1 (STIP1) 13 Metabolic regulators 13 Apolipoprotein E (ApoE) 13 Fatty acid synthase (FASN) 13 Receptors 14 Folate receptor-α (FLOR1) 14 Proteins of unknown function in ovarian cancer 15 i Human epididymis protein 4 (HE4) 15 Mesothelin (MSLN) 15 Prostasin (PRSS8) 16 Shared Computational Characteristics 19 Characteristics of secreted proteins 19 Characteristics of stable proteins 20 Identifying additional key regulators of ovarian cancer 24 Rationale 31 Central Hypothesis 31 Aim 1 32 Aim 2 32 Aim 3 32 Chapter 2 Computational Analysis of Amylase Isozymes Contributing to Ovarian Cancer 34 Introduction 34 History of the amylase genes 34 Evolution and expression of amylase genes 35 Amylase gene regulation 37 Differentiating amylase isozymes 38 Known amylase characteristics 39 Amylase in cancer 40 Objectives 41 Materials and methods 41 Sequences used in computational characterization 41 Amylase isozyme homology 41 Protein biochemical properties databases 41 Protein disorder 42 Secondary structure prediction 42 Posttranslational modification 43 Transcription regulation by promoter analysis 43 Mutational analysis of the amylase isozymes 43 Clinical specimens 44 Western blot 44 Results 45 Amylase isozymes are highly homologous 45 Amylase isozymes have similar molecular weights and isoelectric points 45 Amylases are highly ordered proteins with one predicted protein binding site 45 Amylase isozymes are hydrophilic 50 Amylase is predicted to be glycosylated and phosphorylated 50 The amylase isozymes have common domains, and structural features 51 Amylase isozymes have unique binding regions for chloride, calcium and glucose 52 The amylase isozymes have similar secondary and tertiary structure profiles 54 Multiple regions of amylase are prone to aggregation 55 ii The amylase isozymes functionally interact with metabolic proteins 56 Amylase isozyme expression may be driven by differential promotor activation 59 AMY2B overexpression is the most likely to be associated with amplification mutations in cancer 60 Clinical validation confirms elevated levels of AMY2B protein in OC 67 Discussion 69 Chapter 3 Amylase Promotes Ovarian Cancer Cell Invasion In Vitro 79 Introduction 79 Materials and methods 80 Tissue culture 80 Transmission Electron microscope (TEM) 80 Quantitative PCR 81 Western blot 82 Amylase ELISA 82 Amylase activity assay 83 Amylase transfection 83 Invasion assay 84 Glycosaminoglycan (GAG)/proteoglycan quantitative assay 84 Immunogold staining 84 Statistical analysis 85 Results 85 Confirmation of yeast-free cultures 85 OC cells overexpress amylase in vitro 87 Amylase secreted by OC cells is metabolically active 91 Inhibiting amylase decreases OC invasion 93 The gylcocalyx of OC cells is thicker than the glycocalyx of IOSE cells 94 Inhibiting amylase increases GAG production 98 Discussion 99 Chapter 4 Regulation of amylase by spirulina 103 Introduction 103 Materials and methods 104 Tissue culture 104 Microarray 105 Quantitative PCR 105 Western blot 106 Amylase ELISA 106 Invasion assay 107 MTS assay 107 Statistical analysis 107 Results 108 Amylase is a downstream target of spirulina 108 Spirulina downregulates amylase mRNA expression in OC cell lines 108 Spirulina downregulates amylase protein expression in OC cell lines 109 iii Spirulina reduces amylase secretion by OC cell lines 112 Spirulina decreases the invasive capacity of OC cells 113 Spirulina decreased migration of OVCAR5 cells 113 Spirulina does not alter OC proliferation 115 Phycocyanin abrogates amylase RNA expression 116 Spirulina-induced inhibition of OC invasion is driven, in part, by Phycocyanin 117 Discussion 118 Chapter 5 Concluding Remarks 121 Chapter 6 References 126 Appendix I Potential novel regulators or biomarkers of OC – 683 proteins in total of non-redundant, secreted, ordered and aggregation-prone human proteins. 176 iv List of Tables Table 1.1 Functional and clinical characteristics of OC biomarkers 4 Table 1.2 Computational characteristics of OC biomarkers 17 Table 1.3 Proteins that interact with literature reported ovarian cancer biomarkers 28 Table 2.1 Biochemical properties of amylase determined by computational analyses 47 Table 2.2 Secondary structural and posttranslational modifications among amylase isozymes 51 Table 2.3 Proteins that functionally interact with amylase isozymes 58 Table 2.4 Distinguishing computational characteristics among amylase isozymes 72 Table 3.1 AMY1 and AMY2B are typically overexpressed in cancer cells 91 Table 4.1 Spirulina transcriptionally targets amylase 108 v List of Figures Figure 1.1 OC biomarkers have functional interactions 25 Figure 1.2 Summarial schematic identifying additional protein regulators of OC 26 Figure 1.3 Identification of proteins that interact with literature-derived OC biomarkers 30 Figure 2.1 Schematic of mammalian amylase gene distinction 36 Figure 2.2 Amylase proteins are highly homologous 46 Figure 2.3 Amylase isozymes are ordered proteins 48 Figure 2.4 Amylase isozymes are hydrophilic 49 Figure 2.5 Amylase isozymes share structural features 53 Figure 2.6 AMY2A has a unique 3D structure 54 Figure 2.7 Amylase isozymes have multiple aggregation prone regions 55 Figure 2.8 Amylase isozymes form functional interactions with other metabolic enzymes 57 Figure 2.9 AMY2B has unique potential transcription factors 61 Figure 2.10 Mutational events are highest in AMY2B 62 Figure 2.11 AMY2B is altered in most cancer types 63 Figure 2.12 AMY2B is the most expressed amylase isozyme in OC 66 Figure 2.13
Load more

Recommended publications
  • Purification and Identification of a Binding Protein for Pancreatic
    Biochem. J. (2003) 372, 227–233 (Printed in Great Britain) 227 Purification and identification of a binding protein for pancreatic secretory trypsin inhibitor: a novel role of the inhibitor as an anti-granzyme A Satoshi TSUZUKI*1,2,Yoshimasa KOKADO*1, Shigeki SATOMI*, Yoshie YAMASAKI*, Hirofumi HIRAYASU*, Toshihiko IWANAGA† and Tohru FUSHIKI* *Laboratory of Nutrition Chemistry, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kitashirakawa Oiwake-cho, Sakyo-ku, Kyoto 606-8502, Japan, and †Laboratory of Anatomy, Graduate School of Veterinary Medicine, Hokkaido University, Kita 18-Nishi 9, Kita-ku, Sapporo 060-0818, Japan Pancreatic secretory trypsin inhibitor (PSTI) is a potent trypsin of GzmA-expressing intraepithelial lymphocytes in the rat small inhibitor that is mainly found in pancreatic juice. PSTI has been intestine. We concluded that the PSTI-binding protein isolated shown to bind specifically to a protein, distinct from trypsin, on from the dispersed cells is GzmA that is produced in the the surface of dispersed cells obtained from tissues such as small lymphocytes of the tissue. The rGzmA hydrolysed the N-α- intestine. In the present study, we affinity-purified the binding benzyloxycarbonyl-L-lysine thiobenzyl ester (BLT), and the BLT protein from the 2 % (w/v) Triton X-100-soluble fraction of hydrolysis was inhibited by PSTI. Sulphated glycosaminoglycans, dispersed rat small-intestinal cells using recombinant rat PSTI. such as fucoidan or heparin, showed almost no effect on the Partial N-terminal sequencing of the purified protein gave a inhibition of rGzmA by PSTI, whereas they decreased the inhi- sequence that was identical with the sequence of mouse granzyme bition by antithrombin III.
    [Show full text]
  • Structural Forms of the Human Amylase Locus and Their Relationships to Snps, Haplotypes, and Obesity
    Structural Forms of the Human Amylase Locus and Their Relationships to SNPs, Haplotypes, and Obesity The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Usher, Christina Leigh. 2015. Structural Forms of the Human Amylase Locus and Their Relationships to SNPs, Haplotypes, and Obesity. Doctoral dissertation, Harvard University, Graduate School of Arts & Sciences. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:17467224 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Structural forms of the human amylase locus and their relationships to SNPs, haplotypes, and obesity A dissertation presented by Christina Leigh Usher to The Division of Medical Sciences in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the subject of Genetics and Genomics Harvard University Cambridge, Massachusetts March 2015 © 2015 Christina Leigh Usher All rights reserved. Dissertation Advisor: Professor Steven McCarroll Christina Leigh Usher Structural forms of the human amylase locus and their relationships to SNPs, haplotypes, and obesity Abstract Hundreds of human genes reside in structurally complex loci that elude molecular analysis and assessment in genome-wide association studies (GWAS). One such locus contains the three different amylase genes (AMY2B, AMY2A, and AMY1) responsible for digesting starch into sugar. The copy number of AMY1 is reported to be the genome’s largest influence on obesity, yet has gone undetected in GWAS.
    [Show full text]
  • Chromosome 1 (Human Genome/Inkae) A
    Proc. Nati. Acad. Sci. USA Vol. 89, pp. 4598-4602, May 1992 Medical Sciences Integration of gene maps: Chromosome 1 (human genome/inkae) A. COLLINS*, B. J. KEATSt, N. DRACOPOLIt, D. C. SHIELDS*, AND N. E. MORTON* *CRC Research Group in Genetic Epidemiology, Department of Child Health, University of Southampton, Southampton, S09 4XY, United Kingdom; tDepartment of Biometry and Genetics, Louisiana State University Center, 1901 Perdido Street, New Orleans, LA 70112; and tCenter for Cancer Research, Massachusetts Institute of Technology, 40 Ames Street, Cambridge, MA 02139 Contributed by N. E. Morton, February 10, 1992 ABSTRACT A composite map of 177 locI has been con- standard lod tables extracted from the literature. Multiple structed in two steps. The first combined pairwise logarithm- pairwise analysis of these data was performed by the MAP90 of-odds scores on 127 loci Into a comprehensive genetic map. computer program (6), which can estimate an errorfrequency Then this map was projected onto the physical map through e (7) and a mapping parameter p such that map distance w is cytogenetic assignments, and the small amount ofphysical data a function of 0, e and p (8). It also includes a bootstrap to was interpolated for an additional 50 loci each of which had optimize order and a stepwise elimination of weakly sup- been assigned to an interval of less than 10 megabases. The ported loci to identify a conservative set of reliably ordered resulting composite map is on the physical scale with a reso- (framework) markers. The genetic map was combined with lution of 1.5 megabases.
    [Show full text]
  • Characterization of Genomic Copy Number Variation in Mus Musculus Associated with the Germline of Inbred and Wild Mouse Populations, Normal Development, and Cancer
    Western University Scholarship@Western Electronic Thesis and Dissertation Repository 4-18-2019 2:00 PM Characterization of genomic copy number variation in Mus musculus associated with the germline of inbred and wild mouse populations, normal development, and cancer Maja Milojevic The University of Western Ontario Supervisor Hill, Kathleen A. The University of Western Ontario Graduate Program in Biology A thesis submitted in partial fulfillment of the equirr ements for the degree in Doctor of Philosophy © Maja Milojevic 2019 Follow this and additional works at: https://ir.lib.uwo.ca/etd Part of the Genetics and Genomics Commons Recommended Citation Milojevic, Maja, "Characterization of genomic copy number variation in Mus musculus associated with the germline of inbred and wild mouse populations, normal development, and cancer" (2019). Electronic Thesis and Dissertation Repository. 6146. https://ir.lib.uwo.ca/etd/6146 This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact [email protected]. Abstract Mus musculus is a human commensal species and an important model of human development and disease with a need for approaches to determine the contribution of copy number variants (CNVs) to genetic variation in laboratory and wild mice, and arising with normal mouse development and disease. Here, the Mouse Diversity Genotyping array (MDGA)-approach to CNV detection is developed to characterize CNV differences between laboratory and wild mice, between multiple normal tissues of the same mouse, and between primary mammary gland tumours and metastatic lung tissue.
    [Show full text]
  • Renal Cell Neoplasms Contain Shared Tumor Type–Specific Copy Number Variations
    The American Journal of Pathology, Vol. 180, No. 6, June 2012 Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. http://dx.doi.org/10.1016/j.ajpath.2012.01.044 Tumorigenesis and Neoplastic Progression Renal Cell Neoplasms Contain Shared Tumor Type–Specific Copy Number Variations John M. Krill-Burger,* Maureen A. Lyons,*† The annual incidence of renal cell carcinoma (RCC) has Lori A. Kelly,*† Christin M. Sciulli,*† increased steadily in the United States for the past three Patricia Petrosko,*† Uma R. Chandran,†‡ decades, with approximately 58,000 new cases diag- 1,2 Michael D. Kubal,§ Sheldon I. Bastacky,*† nosed in 2010, representing 3% of all malignancies. Anil V. Parwani,*†‡ Rajiv Dhir,*†‡ and Treatment of RCC is complicated by the fact that it is not a single disease but composes multiple tumor types with William A. LaFramboise*†‡ different morphological characteristics, clinical courses, From the Departments of Pathology* and Biomedical and outcomes (ie, clear-cell carcinoma, 82% of RCC ‡ Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania; cases; type 1 or 2 papillary tumors, 11% of RCC cases; † the University of Pittsburgh Cancer Institute, Pittsburgh, chromophobe tumors, 5% of RCC cases; and collecting § Pennsylvania; and Life Technologies, Carlsbad, California duct carcinoma, approximately 1% of RCC cases).2,3 Benign renal neoplasms are subdivided into papillary adenoma, renal oncocytoma, and metanephric ade- Copy number variant (CNV) analysis was performed on noma.2,3 Treatment of RCC often involves surgical resec- renal cell carcinoma (RCC) specimens (chromophobe, tion of a large renal tissue component or removal of the clear cell, oncocytoma, papillary type 1, and papillary entire affected kidney because of the relatively large size of type 2) using high-resolution arrays (1.85 million renal tumors on discovery and the availability of a life-sus- probes).
    [Show full text]
  • Differential Proteomic Analysis of the Pancreas of Diabetic Db/Db Mice Reveals the Proteins Involved in the Development of Complications of Diabetes Mellitus
    Int. J. Mol. Sci. 2014, 15, 9579-9593; doi:10.3390/ijms15069579 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Article Differential Proteomic Analysis of the Pancreas of Diabetic db/db Mice Reveals the Proteins Involved in the Development of Complications of Diabetes Mellitus Victoriano Pérez-Vázquez 1,*, Juan M. Guzmán-Flores 1, Daniela Mares-Álvarez 1, Magdalena Hernández-Ortiz 2, Maciste H. Macías-Cervantes 1, Joel Ramírez-Emiliano 1 and Sergio Encarnación-Guevara 2 1 Depto. de Ciencias Médicas, División de Ciencias de la Salud, Campus León, Universidad de Guanajuato, León, Guanajuato 37320, Mexico; E-Mails: [email protected] (J.M.G.-F.); [email protected] (D.M.-A.); [email protected] (M.H.M.-C.); [email protected] (J.R.-E.) 2 Centro de Ciencias Genómicas, Universidad Nacional Autónoma de México, Cuernavaca, Morelos 62210, Mexico; E-Mails: [email protected] (M.H.-O.); [email protected] (S.E.-G.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +52-477-7143-812; Fax: +52-477-7167-623. Received: 4 April 2014; in revised form: 14 May 2014 / Accepted: 19 May 2014 / Published: 30 May 2014 Abstract: Type 2 diabetes mellitus is characterized by hyperglycemia and insulin-resistance. Diabetes results from pancreatic inability to secrete the insulin needed to overcome this resistance. We analyzed the protein profile from the pancreas of ten-week old diabetic db/db and wild type mice through proteomics. Pancreatic proteins were separated in two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and significant changes in db/db mice respect to wild type mice were observed in 27 proteins.
    [Show full text]
  • Atrazine and Cell Death Symbol Synonym(S)
    Supplementary Table S1: Atrazine and Cell Death Symbol Synonym(s) Entrez Gene Name Location Family AR AIS, Andr, androgen receptor androgen receptor Nucleus ligand- dependent nuclear receptor atrazine 1,3,5-triazine-2,4-diamine Other chemical toxicant beta-estradiol (8R,9S,13S,14S,17S)-13-methyl- Other chemical - 6,7,8,9,11,12,14,15,16,17- endogenous decahydrocyclopenta[a]phenanthrene- mammalian 3,17-diol CGB (includes beta HCG5, CGB3, CGB5, CGB7, chorionic gonadotropin, beta Extracellular other others) CGB8, chorionic gonadotropin polypeptide Space CLEC11A AW457320, C-type lectin domain C-type lectin domain family 11, Extracellular growth factor family 11, member A, STEM CELL member A Space GROWTH FACTOR CYP11A1 CHOLESTEROL SIDE-CHAIN cytochrome P450, family 11, Cytoplasm enzyme CLEAVAGE ENZYME subfamily A, polypeptide 1 CYP19A1 Ar, ArKO, ARO, ARO1, Aromatase cytochrome P450, family 19, Cytoplasm enzyme subfamily A, polypeptide 1 ESR1 AA420328, Alpha estrogen receptor,(α) estrogen receptor 1 Nucleus ligand- dependent nuclear receptor estrogen C18 steroids, oestrogen Other chemical drug estrogen receptor ER, ESR, ESR1/2, esr1/esr2 Nucleus group estrone (8R,9S,13S,14S)-3-hydroxy-13-methyl- Other chemical - 7,8,9,11,12,14,15,16-octahydro-6H- endogenous cyclopenta[a]phenanthren-17-one mammalian G6PD BOS 25472, G28A, G6PD1, G6PDX, glucose-6-phosphate Cytoplasm enzyme Glucose-6-P Dehydrogenase dehydrogenase GATA4 ASD2, GATA binding protein 4, GATA binding protein 4 Nucleus transcription TACHD, TOF, VSD1 regulator GHRHR growth hormone releasing
    [Show full text]
  • Genomics and Genetics of Gonadotropin Beta-Subunit Genes: Unique FSHB and Duplicated LHB/CGB Loci
    Molecular and Cellular Endocrinology 329 (2010) 4–16 Contents lists available at ScienceDirect Molecular and Cellular Endocrinology journal homepage: www.elsevier.com/locate/mce Review Genomics and genetics of gonadotropin beta-subunit genes: Unique FSHB and duplicated LHB/CGB loci Liina Nagirnaja a, Kristiina Rull a,b,c, Liis Uusküla a, Pille Hallast a, Marina Grigorova a,c, Maris Laan a,∗ a Institute of Molecular and Cell Biology, University of Tartu, Riia St. 23, 51010 Tartu, Estonia b Department of Obstetrics and Gynecology, University of Tartu, Puusepa 8 G2, 51014 Tartu, Estonia c Estonian Biocentre, Riia St. 23b, 51010 Tartu, Estonia article info abstract Article history: The follicle stimulating hormone (FSH), luteinizing hormone (LH) and chorionic gonadotropin (HCG) play Received 5 January 2010 a critical role in human reproduction. Despite the common evolutionary ancestry and functional related- Received in revised form 13 April 2010 ness of the gonadotropin hormone beta (GtHB) genes, the single-copy FSHB (at 11p13) and the multi-copy Accepted 26 April 2010 LHB/CGB genes (at 19q13.32) exhibit locus-specific differences regarding their genomic context, evolu- tion, genetic variation and expressional profile. FSHB represents a conservative vertebrate gene with a Keywords: unique function and it is located in a structurally stable gene-poor region. In contrast, the primate-specific Gonadotropin hormones LHB/CGB gene cluster is located in a gene-rich genomic context and demonstrates an example of evolu- FSHB LHB tionary young and unstable genomic region. The gene cluster is shaped by a constant balance between HCG beta selection that acts on specific functions of the loci and frequent gene conversion events among dupli- Gene duplications cons.
    [Show full text]
  • Chuanxiong Rhizoma Compound on HIF-VEGF Pathway and Cerebral Ischemia-Reperfusion Injury’S Biological Network Based on Systematic Pharmacology
    ORIGINAL RESEARCH published: 25 June 2021 doi: 10.3389/fphar.2021.601846 Exploring the Regulatory Mechanism of Hedysarum Multijugum Maxim.-Chuanxiong Rhizoma Compound on HIF-VEGF Pathway and Cerebral Ischemia-Reperfusion Injury’s Biological Network Based on Systematic Pharmacology Kailin Yang 1†, Liuting Zeng 1†, Anqi Ge 2†, Yi Chen 1†, Shanshan Wang 1†, Xiaofei Zhu 1,3† and Jinwen Ge 1,4* Edited by: 1 Takashi Sato, Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of 2 Tokyo University of Pharmacy and Life Cardio-Cerebral Diseases, Hunan University of Chinese Medicine, Changsha, China, Galactophore Department, The First 3 Sciences, Japan Hospital of Hunan University of Chinese Medicine, Changsha, China, School of Graduate, Central South University, Changsha, China, 4Shaoyang University, Shaoyang, China Reviewed by: Hui Zhao, Capital Medical University, China Background: Clinical research found that Hedysarum Multijugum Maxim.-Chuanxiong Maria Luisa Del Moral, fi University of Jaén, Spain Rhizoma Compound (HCC) has de nite curative effect on cerebral ischemic diseases, *Correspondence: such as ischemic stroke and cerebral ischemia-reperfusion injury (CIR). However, its Jinwen Ge mechanism for treating cerebral ischemia is still not fully explained. [email protected] †These authors share first authorship Methods: The traditional Chinese medicine related database were utilized to obtain the components of HCC. The Pharmmapper were used to predict HCC’s potential targets. Specialty section: The CIR genes were obtained from Genecards and OMIM and the protein-protein This article was submitted to interaction (PPI) data of HCC’s targets and IS genes were obtained from String Ethnopharmacology, a section of the journal database.
    [Show full text]
  • An Investigation Into the Carbonic Anhydrase Isozymes from Zea
    This file is part of the following reference: Tems, Ursula (2009) Characterization of the carbonic anhydrase isozymes of zea mays. PhD thesis, James Cook University. Access to this file is available from: http://eprints.jcu.edu.au/8807 Characterization of the Carbonic Anhydrase Isozymes of Zea mays Thesis submitted by Ursula TEMS B.Sc. Hons (JCU) February 2009 for the degree of Doctor of Philosophy in the School of Pharmacy and Molecular Sciences James Cook University Statement of Sources I declare that this thesis is my own work and has not been submitted in any form for another degree or diploma at any university or other institution of tertiary education. Information derived from the published or unpublished work of others has been acknowledged in the text and a list of references is given. Signature Date i Statement of Access I, the undersigned, author of this work, understand that James Cook University will make this thesis available for use within the University Library and, via the Australian Digital Theses network, for use elsewhere. I understand that, as an unpublished work, a thesis has significant protection under the Copyright Act and; I do not wish to place any further restriction on access to this work. Signature Date Declaration I, the undersigned, the author of this work, declare that the electronic copy of this thesis provided to the James Cook University Library is an accurate copy of the print thesis submitted, within the limits of the technology available. Signature Date ii Acknowledgements I would like to express my sincere gratitude to my supervisor Jim Burnell for his enthusiasm, encouragement and guidance.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Toxicogenomics Applications of New Functional Genomics Technologies in Toxicology
    \-\w j Toxicogenomics Applications of new functional genomics technologies in toxicology Wilbert H.M. Heijne Proefschrift ter verkrijging vand egraa dva n doctor opgeza gva nd e rector magnificus vanWageninge n Universiteit, Prof.dr.ir. L. Speelman, in netopenbaa r te verdedigen op maandag6 decembe r200 4 des namiddagst e half twee ind eAul a - Table of contents Abstract Chapter I. page 1 General introduction [1] Chapter II page 21 Toxicogenomics of bromobenzene hepatotoxicity: a combined transcriptomics and proteomics approach[2] Chapter III page 48 Bromobenzene-induced hepatotoxicity atth etranscriptom e level PI Chapter IV page 67 Profiles of metabolites and gene expression in rats with chemically induced hepatic necrosis[4] Chapter V page 88 Liver gene expression profiles in relation to subacute toxicity in rats exposed to benzene[5] Chapter VI page 115 Toxicogenomics analysis of liver gene expression in relation to subacute toxicity in rats exposed totrichloroethylen e [6] Chapter VII page 135 Toxicogenomics analysis ofjoin t effects of benzene and trichloroethylene mixtures in rats m Chapter VII page 159 Discussion and conclusions References page 171 Appendices page 187 Samenvatting page 199 Dankwoord About the author Glossary Abbreviations List of genes Chapter I General introduction Parts of this introduction were publishedin : Molecular Biology in Medicinal Chemistry, Heijne etal., 2003 m NATO Advanced Research Workshop proceedings, Heijne eral., 2003 81 Chapter I 1. General introduction 1.1 Background /.1.1 Toxicologicalrisk
    [Show full text]